| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/10/2005 | US6890914 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 05/10/2005 | US6890913 Novel chitosan of given degree of deacetylation and weight average molecular weight, production of chitosan from a fungus, and use of chitosan for treating breast or cervical cancer |
| 05/10/2005 | US6890902 Cytotoxic modified lactoferrin peptides |
| 05/10/2005 | US6890899 A lipolytic or lipid mobilising factor (LMF) produced by the cachexia-inducing murine tumor MAC16; weight reduction or controlling obesity; administering a Zn-alpha 2-glycoprotein |
| 05/10/2005 | US6890897 In combination with an osteoinductive protein and a bone morphogenetic protein or a hedgehog protein to induce osteogenesis; biocompatible or biodegradable matrix |
| 05/10/2005 | US6890751 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/10/2005 | US6890709 For induction of S-phase/oncogenicity/transcription/apoptosis in cells |
| 05/10/2005 | US6890546 Stents, catheters, arterio-venous grafts, by-pass grafts and drug delivery ballons with surface coating containing a rapamycin derivative having a tetrazole group |
| 05/10/2005 | CA2330935C A mutant human hepatitis b viral strain and uses thereof |
| 05/10/2005 | CA2320474C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines |
| 05/10/2005 | CA2278290C Quinazolinone compounds |
| 05/10/2005 | CA2222995C Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 05/10/2005 | CA2116192C Highly concentrated tcf pharmaceutical preparations |
| 05/06/2005 | WO2005040221A1 Correlation between the fucose content / galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity |
| 05/06/2005 | WO2005040189A1 Novel dammarane sapogenins and their use as anti-cancer agents |
| 05/06/2005 | WO2005040179A1 Composition originating in lophyllum decastes fruit body |
| 05/06/2005 | WO2005040172A1 Tricyclic proline derivative |
| 05/06/2005 | WO2005040148A1 New rar$g(b) receptor-activating ligand, method for the preparation thereof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | WO2005040045A2 Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum (iv) and use thereof for the production of pharmaceutical agent |
| 05/06/2005 | WO2005039607A1 The use of balloonfish collagen i extractive in medical care and the preparative method of it |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039599A1 Matrix metalloprotease inhibitor containing polylactic acid mixture |
| 05/06/2005 | WO2005039562A1 A use of lancifolide derivatives and the composition comprising the same |
| 05/06/2005 | WO2005039553A1 Compositions for the treatment and prevention of cancer |
| 05/06/2005 | WO2005002607A3 Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| 05/06/2005 | WO2004112839A3 Specific high-relaxivity conjugate compounds for magnetic resonance imaging |
| 05/06/2005 | WO2004081027B1 Neoplasm specific antibodies and uses thereof |
| 05/06/2005 | WO2004080418A3 Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
| 05/06/2005 | WO2004071529A3 Uses of anti-insulin-like growth factor i receptor antibodies |
| 05/06/2005 | WO2004058815B1 Centrosome-associated protein and applications thereof |
| 05/06/2005 | WO2004018619A3 P53 binding t cell receptor molecules and uses thereof |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003018606A3 Casein derived peptides and uses thereof in therapy |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2543630A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof |
| 05/06/2005 | CA2543570A1 Acylurea connected and sulfonylurea connected hydroxamates |
| 05/06/2005 | CA2543565A1 Use of caspase-8 inhibitors for modulating hematopoiesis |
| 05/06/2005 | CA2542967A1 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives |
| 05/06/2005 | CA2542898A1 Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents |
| 05/06/2005 | CA2542881A1 Antibody with an optimized fucose content/galactose content ratio |
| 05/06/2005 | CA2542661A1 Methods and compositions for treating cancer |
| 05/06/2005 | CA2542522A1 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| 05/06/2005 | CA2542419A1 Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia |
| 05/06/2005 | CA2542217A1 Method of administering cationic liposomes comprising an active drug |
| 05/06/2005 | CA2542210A1 Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| 05/06/2005 | CA2542175A1 Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses |
| 05/06/2005 | CA2541693A1 Immunogenic compositions |
| 05/06/2005 | CA2539720A1 1-.prime.(e)-2-(phenyl) ethenyl-4-(arylalkoxy)-oxazole or - thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer |
| 05/06/2005 | CA2539193A1 New rarbeta receptor-activating ligand, method for the preparation ther eof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | CA2538134A1 Novel imidazole derivatives and their use as pharmaceutical agents |
| 05/06/2005 | CA2538131A1 Novel triarylimidazoles |
| 05/06/2005 | CA2537224A1 Heterocycle-substituted pteridine derivatives and their use in therapy |
| 05/06/2005 | CA2534996A1 The use of sirna silencing in the prevention of metastasis |
| 05/06/2005 | CA2532094A1 Sp1 and sp3 targeted cancer therapies and therapeutics |
| 05/05/2005 | US20050096484 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| 05/05/2005 | US20050096473 Reacting 1,1'-thiocarbonyldiimidazole with an aryl amine, e.g., benzylamine, to form 1830 thiourea (or urea)prodoucts; high speed, automatic process; anticarcinogenic agents, leukemia; enzyme inhibitors for HIV reverse transcriptase (polymerase) |
| 05/05/2005 | US20050096469 Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096463 Metastasis inducing DNA's |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096363 Activator of peroxisome proliferator-activated receptor delta |
| 05/05/2005 | US20050096356 2-[[6-Methoxy-3-pyridinyl]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride salt or its tautomer; treating retinopathy or age-related macula degeneration |
| 05/05/2005 | US20050096355 Novel immunotherapeutic agents |
| 05/05/2005 | US20050096345 Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096331 Alkyl carboxylic acids and their derivatives; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds; better efficacy, potency and lower toxicity |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096273 Regulation of matrix metalloproteinases by PSP94 family members |
| 05/05/2005 | US20050096271 Fusion of polypeptides and immunoglobulin protein; immunotherapy ; antiallergens; antiarthritic agents; anticancer agents; antiinflammatory agents |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096229 Biocidal compounds and their preparation |
| 05/05/2005 | US20050095710 Antisense modulation of PTP1B expression |
| 05/05/2005 | US20050095692 Generation and recovering of preferential viral particles; obtain cells, infect with virus, extract virus from cells using detergent, recover virus |
| 05/05/2005 | US20050095686 Preparing starch composition to improve structure, texture and stability of food; for use in prevention and treatment of infection, immunological and tumor disorders |
| 05/05/2005 | US20050095681 Intracellular modulators of apoptopic cell death pathways |
| 05/05/2005 | US20050095675 Mucin peptide with immunoenhancing properties |
| 05/05/2005 | US20050095667 Oligomeric lysine-aspartic acid-glutamic acid-leucine amino acid sequence binding protein suppressor; for amplification of immune response to secreted chaperone proteins |
| 05/05/2005 | US20050095257 Cancer and viral infections vaccines; increased immunogenicity |
| 05/05/2005 | US20050095253 inducing cancer immune response |
| 05/05/2005 | US20050095249 Protein markers for lung cancer and use thereof |
| 05/05/2005 | US20050095230 For treatment of cancer or virus infection (HIV) |
| 05/05/2005 | US20050095226 Down-regulation of DNA repair to enhance sensitivity to p53-mediated suppression |
| 05/05/2005 | US20050095224 Compositions and method for treating hepatitis virus infection |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527784A1 Method for extracting antineoplastic components from Bupleurum scorzonerifolium |
| 05/04/2005 | EP1527178A2 Novel class ii cytokine receptors and uses thereof |
| 05/04/2005 | EP1527177A2 Muc-1 antigen with reduced number of vntr repeat units |
| 05/04/2005 | EP1527171A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 05/04/2005 | EP1527084A2 Promoters exhibiting endothelial cell specificity and methods of using same |
| 05/04/2005 | EP1527081A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 05/04/2005 | EP1527077A2 Pyrrolopyrazines as kinase inhibitors |
| 05/04/2005 | EP1527076A1 Dihydro-dibenzo (b,e) oxepine based selective estrogen receptor modulators, compositions and methods |
| 05/04/2005 | EP1527074A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/04/2005 | EP1527071A1 Isothiazole derivatives useful as anticancer agents |
| 05/04/2005 | EP1527070A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 05/04/2005 | EP1527068A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |